A17
A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research[1].
Product Specifications
CAS Number
2568186-47-8
UNSPSC
12352211
Target
AMPK
Type
Reference compound
Related Pathways
Epigenetics; PI3K/Akt/mTOR
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/a17.html
Purity
99.4
Solubility
10 mM in DMSO
Smiles
O=CO[C@@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCC(N[C@H](CO)C(C)C)=O)C)([H])[C@@]4([C@](C[C@@H](CC4)OC=O)([H])C1)C
Molecular Formula
C31H51NO6
Molecular Weight
533.75
References & Citations
[1]Wang Y, et al. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol. 2020 Oct 1;404:115169.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
AMPKα
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY404003 100 µg
Keratinocyte differentiation associated protein (KRTDAP) (NM_207392) Human Over-expression Lysate
Sign In for Pricing
View Details 
